tiprankstipranks
Trending News
More News >
BML Inc (JP:4694)
:4694

BML (4694) AI Stock Analysis

Compare
0 Followers

Top Page

JP

BML

(Munich:4694)

Rating:78Outperform
Price Target:
¥3,826.00
▲(17.90%Upside)
The overall stock score is primarily driven by strong financial performance and robust technical indicators. Despite challenges in revenue and cash flow stability, the stock's technical momentum and fair valuation support a positive outlook.

BML (4694) vs. iShares MSCI Japan ETF (EWJ)

BML Business Overview & Revenue Model

Company DescriptionBML, Inc. provides laboratory testing and related services in Japan. The company offers general laboratory tests, including biochemical and hematologic examinations; special laboratory tests, such as RIA, cellular, immunological, and DNA analysis; microbiological tests for medical and pharmaceutical societies and organizations; and laboratory tests in tumorology, infectious disease, diabetes, hypertension, allergy, and genetic studies. It also develops Frontier and Symphony automation systems, which automate pre-processing procedures from sorting to dispensing, and subsequent test procedures; and provides electronic medical charts for networking medical information, as well as offers preventive medicine services. In addition, the company provides food sanitation control and food processing services comprising contract services for microorganism testing of raw materials, and prepared and processed foods; environmental hygiene testing of food processing facilities and kitchens; and microorganism testing services, as well as assesses genetically modified organisms. Further, it provides drinking water and waste water tests; work sanitation management services, such as measurement of ethylene oxide gas, formaldehyde, organic solvents, and dust; environmental monitoring services, including measurement of indoor contaminants and other indoor environmental variables; and biological dioxin monitoring services. Additionally, the company offers analysis services for residual agricultural chemicals; dental test services for dental caries and periodontal diseases; consulting services for the approval of pharmaceuticals; investigative analysis services to pharmaceutical manufacturers; and gene expression analysis and testing for genes that cause susceptibility to infectious diseases. BML, Inc. was founded in 1955 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyBML (4694) generates revenue through multiple streams within its financial services offerings. The primary source of income is derived from interest earned on loans and credit products extended to retail and corporate clients. Additionally, the company earns fees and commissions from various banking services, such as asset management, transaction processing, and advisory services. Investment banking activities, including underwriting and trading, also contribute to the company's revenue. BML may engage in strategic partnerships with other financial institutions to enhance its service offerings and expand its client base, further driving its earnings.

BML Financial Statement Overview

Summary
BML displays solid financial strength with strong profitability and a robust balance sheet, indicating financial stability. However, declining revenue and fluctuating free cash flow may pose future challenges.
Income Statement
78
Positive
BML exhibits strong profitability indicators with a consistent gross profit margin and a healthy net profit margin, reflecting effective cost management and strong revenue generation. However, the company has experienced a decline in revenue over recent years, which could be a concern for future growth. The EBIT and EBITDA margins indicate efficient operations, although they have decreased from prior years, suggesting room for improving operational efficiency.
Balance Sheet
85
Very Positive
BML maintains a robust balance sheet with a strong equity base and a low debt-to-equity ratio, indicating financial stability and a low risk of financial distress. The equity ratio suggests strong capitalization, providing a solid buffer against liabilities. The return on equity has remained healthy, showcasing efficient use of shareholders' funds despite a decrease in net income in recent periods.
Cash Flow
70
Positive
BML's cash flow management appears stable, with positive operating cash flow supporting its operations. However, free cash flow has fluctuated significantly, pointing to potential volatility in capital expenditures and investment activities. The operating cash flow to net income ratio demonstrates the company's ability to convert income into cash, although the volatility in free cash flow indicates potential challenges in maintaining consistent cash generation.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue141.33B143.19B137.96B159.46B186.07B138.57B
Gross Profit46.11B45.86B45.63B61.45B86.95B54.77B
EBITDA16.82B17.51B16.42B30.57B56.26B26.50B
Net Income6.08B6.26B6.03B15.58B33.74B13.71B
Balance Sheet
Total Assets173.87B177.51B170.99B168.94B179.20B139.17B
Cash, Cash Equivalents and Short-Term Investments66.42B67.56B74.11B86.52B92.13B63.48B
Total Debt4.31B5.29B5.26B4.15B3.33B3.25B
Total Liabilities41.89B43.73B40.85B42.20B57.52B46.05B
Stockholders Equity127.65B129.40B125.86B122.49B116.20B88.42B
Cash Flow
Free Cash Flow0.00663.00M-6.48B5.28B38.52B15.38B
Operating Cash Flow0.0015.81B14.45B11.74B45.60B19.57B
Investing Cash Flow0.00-16.79B-21.14B-7.63B-7.30B-4.58B
Financing Cash Flow0.00-5.43B-5.73B-9.71B-9.83B-3.38B

BML Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3245.00
Price Trends
50DMA
3011.68
Positive
100DMA
2921.11
Positive
200DMA
2817.84
Positive
Market Momentum
MACD
73.14
Negative
RSI
64.42
Neutral
STOCH
61.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4694, the sentiment is Positive. The current price of 3245 is above the 20-day moving average (MA) of 3153.10, above the 50-day MA of 3011.68, and above the 200-day MA of 2817.84, indicating a bullish trend. The MACD of 73.14 indicates Negative momentum. The RSI at 64.42 is Neutral, neither overbought nor oversold. The STOCH value of 61.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4694.

BML Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
€125.97B20.144.86%3.09%3.79%3.75%
76
Outperform
¥64.03B13.37
2.08%2.06%-32.48%
51
Neutral
$7.36B0.28-61.07%2.37%17.46%1.71%
$1.26B69.371.91%3.80%
71
Outperform
¥57.12B11.60
4.39%22.55%-10.96%
68
Neutral
¥68.08B32.86
2.54%1.22%-8.83%
66
Neutral
¥22.70B12.50
5.54%0.71%19.35%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4694
BML
3,245.00
483.28
17.50%
MRCHF
HUGroup Holdings
22.18
8.20
58.66%
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,361.00
-49.65
-3.52%
JP:4549
Eiken Chemical Co., Ltd.
2,124.00
-41.97
-1.94%
JP:4671
FALCO HOLDINGS Co., Ltd
2,263.00
80.99
3.71%
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,398.00
-225.65
-8.60%

BML Corporate Events

BML, Inc. Announces Key Personnel Changes
May 9, 2025

BML, Inc. has announced a series of personnel changes following a board meeting on May 9, 2025. These changes, which involve several key positions within the company, will be finalized at the upcoming Annual General Meeting of Shareholders. The adjustments in leadership roles are expected to streamline operations and enhance the company’s strategic focus, potentially impacting its market positioning and stakeholder relations.

BML, Inc. Announces Governance Transition with New Director Appointments
May 9, 2025

BML, Inc. announced a transition to a company with an Audit and Supervisory Committee, which involves several personnel changes. The proposed candidates for director positions will be submitted for approval at the upcoming Annual General Meeting of Shareholders. This transition is expected to enhance the company’s governance structure and oversight capabilities.

BML, Inc. Proposes Amendments to Enhance Corporate Governance
May 9, 2025

BML, Inc. has announced a proposal for amendments to its Articles of Incorporation, which will be presented at the upcoming Annual General Meeting of Shareholders. The proposed changes are part of a transition to a Company with an Audit and Supervisory Committee, aimed at enhancing corporate governance by strengthening audit and supervisory functions. This transition involves integrating audit and supervisory committee members into the Board of Directors, necessitating changes in the company’s governance framework.

BML, Inc. Reports Fiscal 2024 Earnings with Increased Dividends
May 9, 2025

BML, Inc. reported its fiscal 2024 earnings, showing a modest increase in net sales and profits compared to the previous year, despite a challenging market environment. The company announced a significant increase in dividends, reflecting confidence in its financial stability and commitment to returning value to shareholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 07, 2025